San Francisco startup Framework Therapeutics is additionally focusing on an oral, as soon as-each day GLP-1 drug named GSBR-1290—the drug surpassed Wall Road’s anticipations in June whenever a mid-phase study confirmed average weight loss of all around 6% and it ideas to get started on A further mid-phase trial towards the top of this yr—that